



Amal Therapeutics to publish R&D outcomes in Molecular Therapy

Geneva, Switzerland, July 5, 2016 – Amal Therapeutics announced today that part of its recent research findings about the enhancement of anti-tumor immune responses through optimized combination of adjuvant and cell-penetrating peptide based-vaccines, is available on-line on the Molecular Therapy website on Tuesday July 5, 2016.

[http://www.cell.com/molecular-therapy-family/molecular-therapy/pdf/S1525-0016\(16\)45343-8.pdf](http://www.cell.com/molecular-therapy-family/molecular-therapy/pdf/S1525-0016(16)45343-8.pdf)

The publication highlights the role of in vivo testing when combining novel vaccine constructs together with adjuvants. This critical validation step helps identifying and selecting the best adjuvant/vaccine combinations for further development. *“The results obtained are underlining the importance of adjuvants screening to evaluate in vivo efficacy when using aggressive mouse tumor models”*, said Dr. Derouazi, CEO of Amal Therapeutics. *“We clearly demonstrated that the adjuvant is a critical parameter that could ensure an optimized and potent anti-tumor immunity. We are proud that the quality of our work was recognized by Molecular Therapy”*, added Dr. Derouazi.

About Molecular Therapy

Molecular Therapy (*ISSN 1525-0016 and eISSN 1525-0024*) is the leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide- and protein-, oligonucleotide-, and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Available in print and online, Molecular Therapy is dedicated to promoting the sciences in genetics, medicine, and biotechnology.

<http://www.cell.com/molecular-therapy-family/home>, editor@molther.org

About Amal Therapeutics

Amal Therapeutics SA is a privately held Swiss biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology.

www.amaltherapeutics.com, contact@amaltherapeutics.com